Works matching IS 10837159 AND DT 2023 AND VI 28 AND IP 5
Results: 27
Correction to: Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake.
- Published in:
- 2023
- Publication type:
- Correction Notice
Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e304, doi. 10.1093/oncolo/oyad077
- By:
- Publication type:
- Article
Missed Opportunities in Geriatric Oncology Research.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 373, doi. 10.1093/oncolo/oyad072
- By:
- Publication type:
- Article
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.
- Published in:
- 2023
- Publication type:
- Correction Notice
Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 376, doi. 10.1093/oncolo/oyad066
- By:
- Publication type:
- Article
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e263, doi. 10.1093/oncolo/oyad053
- By:
- Publication type:
- Article
Emerging Trends in Immunotherapy for Adult Sarcomas.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e233, doi. 10.1093/oncolo/oyad052
- By:
- Publication type:
- Article
Revisiting Androgen Receptor Signaling in Breast Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 383, doi. 10.1093/oncolo/oyad049
- By:
- Publication type:
- Article
Associations Between Psycho-Social-Spiritual Interventions, Fewer Aggressive End-of-Life Measures, and Increased Time After Final Oncologic Treatment.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e287, doi. 10.1093/oncolo/oyad037
- By:
- Publication type:
- Article
The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial Terms.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 379, doi. 10.1093/oncolo/oyad034
- By:
- Publication type:
- Article
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 460, doi. 10.1093/oncolo/oyad023
- By:
- Publication type:
- Article
Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 414, doi. 10.1093/oncolo/oyad021
- By:
- Publication type:
- Article
Correction to: Management of Lung Cancer in the Patient with Interstitial Lung Disease.
- Published in:
- 2023
- Publication type:
- Correction Notice
Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 462, doi. 10.1093/oncolo/oyad017
- By:
- Publication type:
- Article
Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e270, doi. 10.1093/oncolo/oyad016
- By:
- Publication type:
- Article
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e309, doi. 10.1093/oncolo/oyad008
- By:
- Publication type:
- Article
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e242, doi. 10.1093/oncolo/oyad005
- By:
- Publication type:
- Article
Childhood Cancer Survivors' Reported Late Effects, Motivations for Seeking Survivorship Care, and Patterns of Attendance.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e276, doi. 10.1093/oncolo/oyad004
- By:
- Publication type:
- Article
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 425, doi. 10.1093/oncolo/oyad002
- By:
- Publication type:
- Article
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 449, doi. 10.1093/oncolo/oyac280
- By:
- Publication type:
- Article
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 392, doi. 10.1093/oncolo/oyac279
- By:
- Publication type:
- Article
Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 453, doi. 10.1093/oncolo/oyac272
- By:
- Publication type:
- Article
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 402, doi. 10.1093/oncolo/oyac264
- By:
- Publication type:
- Article
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 433, doi. 10.1093/oncolo/oyac262
- By:
- Publication type:
- Article
Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. e254, doi. 10.1093/oncolo/oyac261
- By:
- Publication type:
- Article
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
- Published in:
- Oncologist, 2023, v. 28, n. 5, p. 440, doi. 10.1093/oncolo/oyac252
- By:
- Publication type:
- Article
Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
- Published in:
- 2023
- Publication type:
- Correction Notice